No profile data available.
Senti Biosciences, Inc. (SNTI) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in South San Francisco, United States, with about 39 full-time employees.
It reported revenue of $22,000 for fiscal year 2025, and net income of -$61.44 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $17,000. Its market capitalization was $9.79 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases.
Senti Biosciences reported $22,000 in revenue for fiscal year 2025. In Q2 2026 revenue was $17,000.
$9.79 million as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Aspire Biopharma Holdings, Inc. (ASBP), Aptorum Group Limited (APM), Theriva Biologics, Inc. (TOVX), Mangoceuticals, Inc. (MGRX).